Parkinson's disease motor complications and advanced therapies
Fluctuations, dyskinesia and device therapy · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Management of wearing-off, on-off fluctuations and levodopa-induced dyskinesia in established Parkinson's disease, and escalation to device-assisted therapies when oral medication fails. Aims to smooth motor response and preserve quality of life.
Red flags
- Impulse control disorder (gambling, hypersexuality) on dopamine agonists
- Hallucinations or psychosis
- Severe freezing with falls
- Dopamine agonist withdrawal syndrome
- Sudden off periods with immobility and aspiration risk
Assessment
Differential diagnosis
- Disease progression versus suboptimal dosing
- Non-motor fluctuations
- Dopamine dysregulation syndrome
- Peak-dose versus diphasic dyskinesia
- Psychogenic movements
- Medication malabsorption (gastroparesis)
Investigations
- Detailed motor diary mapping on/off time and dyskinesia
- Medication timing and dietary protein review
- Assess for gastroparesis affecting absorption
- Cognitive and psychiatric screen before device therapy
- MRI brain for DBS planning
- Review non-motor symptoms (mood, sleep, autonomic)
Management
- Map the pattern of fluctuations and dyskinesia with a timed diary
- Optimise oral levodopa: shorten dosing intervals and consider taking before meals
- Add a COMT inhibitor or MAO-B inhibitor to extend levodopa effect
- Add or adjust a dopamine agonist, balancing against impulse control risk
- Use amantadine to suppress troublesome dyskinesia
- Treat peak-dose dyskinesia by reducing individual levodopa doses and increasing frequency
- Screen for impulse control disorders at every review
- Refer for device-assisted therapy when oral optimisation fails: deep brain stimulation, apomorphine infusion or intestinal levodopa gel
- Address non-motor fluctuations and comorbidities
- Involve specialist Parkinson's nurse and multidisciplinary team
Drugs & doses
Levodopa/carbidopa dose fractionation (smaller, more frequent doses)
Entacapone 200 mg PO with each levodopa dose (COMT inhibitor)
Rasagiline 1 mg PO daily or safinamide 50-100 mg PO daily (MAO-B inhibitor)
Amantadine 100 mg PO BD-TDS for dyskinesia
Apomorphine subcutaneous: intermittent 2-6 mg rescue or continuous infusion
Levodopa-carbidopa intestinal gel via PEG-J
Opicapone 50 mg PO daily as alternative COMT inhibitor
Disposition
Specialist movement disorder clinic. Refer to tertiary centre for DBS or infusion therapies. Parkinson's specialist nurse support.
Complications & pitfalls
- Disabling dyskinesia
- Impulse control disorders
- Dopamine dysregulation syndrome
- Psychosis and cognitive decline
- Device-related complications (infection, hardware, stoma issues)
Exam pearls
- Smaller, more frequent levodopa doses smooth wearing-off; amantadine targets dyskinesia
- Always screen for impulse control disorders with dopamine agonists
- Never stop dopaminergic therapy abruptly (risk of akinetic crisis/NMS-like syndrome)
- Refer for device therapy before patients become too frail or cognitively impaired to benefit
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.